36 related articles for article (PubMed ID: 28500740)
1. Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control study.
Junk SV; Förster A; Schmidt G; Zimmermann M; Fedders B; Haermeyer B; Bergmann AK; Möricke A; Cario G; Auber B; Schrappe M; Kratz CP; Stanulla M
Leukemia; 2024 Apr; 38(4):887-892. PubMed ID: 38413718
[No Abstract] [Full Text] [Related]
2. Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia.
Jones GL; McClellan W; Raman S; Sherman A; Guest E; August K
J Pediatr Hematol Oncol; 2017 Jul; 39(5):370-375. PubMed ID: 28538500
[TBL] [Abstract][Full Text] [Related]
3. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K
Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968
[TBL] [Abstract][Full Text] [Related]
4. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Åsberg A; Frandsen TL; Marquart HV; Madsen HO; Norén-Nyström U; Schmiegelow K
Leukemia; 2018 Mar; 32(3):606-615. PubMed ID: 28819280
[TBL] [Abstract][Full Text] [Related]
5. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
6. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
[TBL] [Abstract][Full Text] [Related]
7. Germline ETV6 mutations and predisposition to hematological malignancies.
Feurstein S; Godley LA
Int J Hematol; 2017 Aug; 106(2):189-195. PubMed ID: 28555414
[TBL] [Abstract][Full Text] [Related]
8. Electrocardiography's role in screening for cardiotoxicity in adult survivors of childhood cancer survivors treated with anthracyclines: Time for a true prospective study?
Adams MJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544783
[No Abstract] [Full Text] [Related]
9. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
Abaji R; Krajinovic M
Pharmgenomics Pers Med; 2017; 10():143-156. PubMed ID: 28507448
[TBL] [Abstract][Full Text] [Related]
10. IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate
Ågerstam H; Lilljebjörn H; Rissler M; Sandén C; Fioretos T
Haematologica; 2023 Feb; 108(2):599-604. PubMed ID: 36226493
[No Abstract] [Full Text] [Related]
11. Polo-like kinases and acute leukemia.
Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
Oncogene; 2019 Jan; 38(1):1-16. PubMed ID: 30104712
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
16. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease.
Harrison CJ
Blood; 2015 Feb; 125(9):1383-6. PubMed ID: 25608562
[TBL] [Abstract][Full Text] [Related]
17. Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.
Nielsen SN; Eriksson F; Rosthoej S; Andersen MK; Forestier E; Hasle H; Hjalgrim LL; Aasberg A; Abrahamsson J; Heyman M; Jónsson ÓG; Pruunsild K; Vaitkeviciené GE; Vettenranta K; Schmiegelow K
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28500740
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
